According to a scientist, trial data of the potential COVID-19 vaccine developed by Oxford University and AstraZeneca is likely to be made available to regulators by this year.
Although, nothing could be done about speeding up approval for emergency use of the vaccine. Oxford vaccine is presently leading among other Covid-19 vaccine candidates that are in the race to put the coronavirus pandemic on end. Oxford vaccine was proven to be successful in the very first clinical trial.
Andrew Pollard, director of the Oxford Vaccine Group said, “It is just possible that if the cases accrue rapidly in the clinical trials, that we could have that data before regulators this year. Then there would be a process that they go through in order to make a full assessment of the data.”
The US Administration is likely to give emergency approval to the vaccine ahead of the US Presidential election 2020, based on the findings of a small UK study conducted on around 10,000 participants.
Pollard, the chief investigator of the global clinical trials of the potential COVID-19 vaccine candidate said, “Oxford had enrolled about 20,000 people in trials across Britain, Brazil and South Africa, with AstraZeneca leading a U.S. trial of 30,000 people. The size of the trials still isn’t the issue here, what you need is to have enough cases accruing during the time of observation in the trials”.